International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 3 , Pages 670-676 , 1 July 2010

Chemoradiotherapy of Newly Diagnosed Glioblastoma With Intensified Temozolomide

Presented orally at the Eighth Meeting of the European Association of Neuro-Oncology, September 12–14, 2008, Barcelona, Spain.

  • Markus Weiler, M.D.

      Affiliations

    • Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
    • Department of Neurooncology, University of Heidelberg, Heidelberg, Germany
    • ,
  • Christian Hartmann, M.D.

      Affiliations

    • Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany
    • ,
  • Dorothee Wiewrodt, M.D.

      Affiliations

    • Department of Neurosurgery, University of Mainz, Mainz, Germany
    • ,
  • Ulrich Herrlinger, M.D.

      Affiliations

    • Clinical Neurooncology Unit, Department of Neurology, University of Bonn, Bonn, Germany
    • ,
  • Thierry Gorlia, M.Sc.

      Affiliations

    • European Organization for Research and Treatment of Cancer Data Centre, Brussels, Belgium
    • ,
  • Oliver Bähr, M.D.

      Affiliations

    • Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
    • ,
  • Richard Meyermann, M.D.

      Affiliations

    • Department of Neuropathology, University of Tübingen, Tübingen, Germany
    • ,
  • Michael Bamberg, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Tübingen, Tübingen, Germany
    • ,
  • Marcos Tatagiba, M.D.

      Affiliations

    • Department of Neurosurgery, University of Tübingen, Tübingen, Germany
    • ,
  • Andreas von Deimling, M.D.

      Affiliations

    • Department of Neuropathology, University of Heidelberg, Heidelberg, Germany
    • ,
  • Michael Weller, M.D.

      Affiliations

    • Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
    • Department of Neurology, University Hospital of Zurich, Zurich, Switzerland
    • ,
  • Wolfgang Wick, M.D.

      Affiliations

    • Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
    • Department of Neurooncology, University of Heidelberg, Heidelberg, Germany
    • Corresponding Author InformationReprint requests to: Wolfgang Wick, M.D., Department of Neurooncology, University of Heidelberg, Im Neuenheimer Feld 400, Heidelberg D-69120 Germany. Tel: (+49) 6221-56-7075; Fax: (+49) 6221-56-7554

Received 23 February 2009 ,Revised 24 May 2009 ,Accepted 26 May 2009.

References 

  1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996
  2. Gerson SL. MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4:296–307
  3. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003
  4. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004–1011
  5. Tosoni A, Cavallo G, Ermani M, et al. Is protracted low-dose temozolomide feasible in glioma patients?. Neurology. 2006;66:427–429
  6. Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007;25:3357–3361
  7. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588–593
  8. Choy H, Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance?. J Natl Cancer Inst. 2003;95:1440–1452
  9. Lundholm K, Gelin J, Hyltander A, et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 1994;54:5602–5606
  10. Bradbury CM, Markovina S, Wei SJ, et al. Indomethacin-induced radiosensitization and inhibition of ionizing radiation-induced NF-kappaB activation in HeLa cells occur via a mechanism involving p38 MAP kinase. Cancer Res. 2001;61:7689–7696
  11. Sengupta S, Sellers LA, Cindrova T, et al. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis. Cancer Res. 2003;63:8351–8359
  12. Shono T, Tofilon PJ, Bruner JM, et al. Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res. 2001;61:4375–4381
  13. Combs SE, Gutwein S, Schulz-Ertner D, et al. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme: Phase I/II study. Strahlenther Onkol. 2005;181:372–377
  14. MacDonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–1280
  15. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  16. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008;9:29–38
  17. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350–1354
  18. Stupp R, Goldbrunner R, Neyns B, et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma [Abstract]. J Clin Oncol. 2007;25(Suppl.):18S
  19. Herrlinger U, Rieger J, Koch D, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol. 2006;24:4412–4417
  20. Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006;24:2563–2569
  21. Neyns B, van Mierlo B, Menten J, et al. A phase II study of temozolomide administered 21 out of 28 days for the treatment of patients with recurrent anaplastic (oligo)astrocytoma: An interim analysis of toxicity [Abstract]. J Clin Oncol. 2005;23(Suppl.):16S
  22. Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from Gruppo Italiano Cooperativo di Neuro-oncologia (GICNO). Br J Cancer. 2006;95:1155–1160
  23. Chinot OL, Barrie M, Fuentes S, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol. 2007;25:1470–1475
  24. Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005;23:2372–2377

 Supported by the University of Tübingen Medical Center, Tübingen, Germany.

 Conflict of interest: U. Herrlinger, M. Weller, and W. Wick have been consultants to, and have received honoraria from, Schering-Plough.

PII: S0360-3016(09)00794-9

doi: 10.1016/j.ijrobp.2009.05.031

International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 3 , Pages 670-676 , 1 July 2010

Article Tools

* Image Usage & Resolution